title: Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study.
abstract: Fractionated doses have been advocated to prevent chemoperitonitis after intraperitoneal infusion of mitoxantrone. Patients with peritoneal carcinomatosis of various origin underwent surgery, including intestinal resections, with minimal residual disease. Peritoneal mitoxantrone in 1000 ml/m(2) saline was planned on the first post-operative day in groups of four patients (5 mg/m(2) for 3 and 5 days, 7.5 mg/m(2) for 3 and 4 days, 10 mg/m(2) for 2-4 days, if possible). Due to dose-limiting myelosuppression, only one and three patients received the 7.5-mg 4-day and 10-mg 3-day regimens, respectively. A total of 20 patients were consequently treated. Neither major complications nor severe pain were observed. Pharmacokinetics were completed on the 1st day in five 5-mg and five 10-mg patients, on the 5th day in three 5-mg patients, and on the 3rd day in one 10-mg patient. On the 1st day, mean peritoneal peak concentrations of mitoxantrone resulted 1.45 +/-0.56 (range 0.48-1.9) and 1.9+/-0.85 (range 1.27-3.13) microg/ml in the 5-mg and 10-mg patients, respectively. Mean dialysate/plasma exposure (AUC) ratio was 115. Even in patients with sutures, early post-operative fractionated intraperitoneal mitoxantrone appears feasible and safe, with a high local advantage, for up to 5 days of treatment and a maximum tolerated total dose of 20-25 mg/m(2).
authors.affiliation: Università di Genova, Facoltà di Medicina e Chirurgia, Dipartimento di Chirurgia DICMI, Largo Rosanna Benzi 8, Genova, 16132, Italy. civa@unige.it
authors.forename: D
authors.initials: D
authors.lastname: Civalleri
authors.forename: M O
authors.initials: MO
authors.lastname: Vannozzi
authors.forename: F
authors.initials: F
authors.lastname: De Cian
authors.forename: F
authors.initials: F
authors.lastname: DeCian
authors.forename: G
authors.initials: G
authors.lastname: Lunardi
authors.forename: M
authors.initials: M
authors.lastname: Steinweg
authors.forename: I
authors.initials: I
authors.lastname: Pastrone
authors.forename: M
authors.initials: M
authors.lastname: Viale
authors.forename: M
authors.initials: M
authors.lastname: Esposito
mesh_terms: D000328:Adult; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D008942:Mitoxantrone